表紙
市場調査レポート

Clazakizumab (関節リウマチ治療薬) - 2023年までの予測と市場分析

Clazakizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325965
出版日 ページ情報 英文 85 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Clazakizumab (関節リウマチ治療薬) - 2023年までの予測と市場分析 Clazakizumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 85 Pages
概要

当レポートでは、関節リウマチの治療薬であるClazakizumabについて調査しており、関節リウマチの概要や治療薬の競合動向、アンメットニーズと機会、製品情報、売上予測などを提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 疾患と治療の概要
    • 診断
    • 治療ガイドライン
    • 関節リウマチ治療のための主な処方薬
    • 臨床診療

第5章 競合評価

  • 概要

第6章 アンメットニーズと機会

  • 概要
  • 費用対効果の高い治療薬の開発
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • バイオマーカーで治療への反応性を予測
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 早期診断
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 個別化医療
    • アンメットニーズ
    • ギャップ分析
    • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発における有望な治療薬

第8章 Clazakizumab

  • 概要
  • 有効性
  • 安全性
  • 投与と処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

目次
Product Code: GDHC506DFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Clazakizumab is a humanized mAb directed against IL-6 that is in Phase IIb of development by Alder Biopharmaceuticals for the treatment of moderate to severe RA. It is expected to be used as an SC injection, in combination with MTX, but is also under investigation for use as a monotherapy. Clazakizumab blocks IL-6 and therefore reduces inflammation, as well as swelling, pain, and joint destruction, associated with RA.

Scope

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Clazakizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Clazakizumab for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Clazakizumab performance.
  • Obtain sales forecast for Clazakizumab from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Development of Cost-Effective Therapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Biomarkers to Predict Responsiveness to Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Early Diagnosis of RA
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Clazakizumab

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed RA Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic and Biosimilar Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Reviewer
    • 9.7.3. Therapy Area Director
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 8: Leading Branded Treatments for RA 2014
  • Table 9: Unmet Need and Opportunity in RA, 2014
  • Table 10: Comparison of Therapeutic Drug Classes in Development for RA, 2014
  • Table 11: Product Profile - Clazakizumab
  • Table 12: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks
  • Table 13: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks
  • Table 14: Clazakizumab SWOT Analysis, 2014
  • Table 15: Global Sales Forecasts ($m) for Clazakizumab, 2013-2023
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
  • Figure 6: RA - Phase II-III Pipeline, 2014
  • Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023
  • Figure 8: Clinical and Commercial Positioning of Clazakizumab
Back to Top